Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Roblin

Showing results (201-210 of 252) with videos related to

Pageof 26
Sort By:
Alimentary Pharmacology & Therapeutics|April 27, 2022
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE StudyNiels Vande Casteele, William J Sandborn, Brian G Feagan, et al.
BMC Gastroenterology|March 28, 2024
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trialsLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Inflammatory Bowel Diseases|January 9, 2007
Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitisFady Daniel, Marie-Anne Loriot, Philippe Seksik, et al.
Journal of Crohn'S & Colitis|August 25, 2025
Comparing standard versus intensified pneumococcal vaccination regimens in patients with inflammatory bowel disease on biologics: a prospective, multicenter, randomized, open-label studyXavier Roblin, Sophie Vieujean, Stéphane Nancey, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 17, 2019
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitisLoriane Lair-Mehiri, Carmen Stefanescu, Thibaut Vaysse, et al.
Therapeutic Advances in Gastroenterology|October 13, 2025
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysisMarc Ferrante, Laurent Peyrin-Biroulet, Perttu Arkkila, et al.
World Journal of Gastroenterology|May 20, 2017
Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practiceShomron Ben-Horin, Jane M Andrews, Konstantinos H Katsanos, et al.
Journal of Crohn'S & Colitis|September 8, 2020
Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter StudyMathurin Fumery, Laurent Peyrin-Biroulet, Stephane Nancey, et al.
Gut Microbes|May 31, 2022
Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancerAonghus Lavelle, Stéphane Nancey, Jean-Marie Reimund, et al.
Journal of Clinical Medicine|April 13, 2023
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort StudyAhmad Albshesh, Lian Bannon, Tali Sharar Fischler, et al.
Pageof 26

Showing results (201-210 of 252) with videos related to

Sort By:
Pageof 26
Alimentary Pharmacology & Therapeutics|April 27, 2022
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE StudyNiels Vande Casteele, William J Sandborn, Brian G Feagan, et al.
BMC Gastroenterology|March 28, 2024
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trialsLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Inflammatory Bowel Diseases|January 9, 2007
Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitisFady Daniel, Marie-Anne Loriot, Philippe Seksik, et al.
Journal of Crohn'S & Colitis|August 25, 2025
Comparing standard versus intensified pneumococcal vaccination regimens in patients with inflammatory bowel disease on biologics: a prospective, multicenter, randomized, open-label studyXavier Roblin, Sophie Vieujean, Stéphane Nancey, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 17, 2019
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitisLoriane Lair-Mehiri, Carmen Stefanescu, Thibaut Vaysse, et al.
Therapeutic Advances in Gastroenterology|October 13, 2025
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysisMarc Ferrante, Laurent Peyrin-Biroulet, Perttu Arkkila, et al.
World Journal of Gastroenterology|May 20, 2017
Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practiceShomron Ben-Horin, Jane M Andrews, Konstantinos H Katsanos, et al.
Journal of Crohn'S & Colitis|September 8, 2020
Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter StudyMathurin Fumery, Laurent Peyrin-Biroulet, Stephane Nancey, et al.
Gut Microbes|May 31, 2022
Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancerAonghus Lavelle, Stéphane Nancey, Jean-Marie Reimund, et al.
Journal of Clinical Medicine|April 13, 2023
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort StudyAhmad Albshesh, Lian Bannon, Tali Sharar Fischler, et al.
Pageof 26